Alnylam Pharmaceuticals
ALNY
#631
Rank
โ‚ฌ33.70 B
Marketcap
252,58ย โ‚ฌ
Share price
-4.32%
Change (1 day)
4.55%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): โ‚ฌ0.49 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ3.71 Billion. , an increase over its 2024 earnings that were of -โ‚ฌ0.21 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 โ‚ฌ0.49 B-344.47%
2024 -โ‚ฌ0.21 Billion-24.59%
2023 -โ‚ฌ0.27 Billion-67.84%
2022 -โ‚ฌ0.83 Billion36.93%
2021 -โ‚ฌ0.61 Billion-8.04%
2020 -โ‚ฌ0.66 Billion-15.66%
2019 -โ‚ฌ0.78 Billion12.23%
2018 -โ‚ฌ0.7 Billion62.91%
2017 -โ‚ฌ0.43 Billion17.78%
2016 -โ‚ฌ0.37 Billion43.44%
2015 -โ‚ฌ0.26 Billion60.69%
2014 -โ‚ฌ0.16 Billion98.2%
2013 -โ‚ฌ79.28 Million
2011 -โ‚ฌ46.76 Million27.48%
2010 -โ‚ฌ36.68 Million-10.92%
2009 -โ‚ฌ41.18 Million95.77%
2008 -โ‚ฌ21.04 Million
2006 -โ‚ฌ33.7 Million-9.13%
2005 -โ‚ฌ37.09 Million34.74%
2004 -โ‚ฌ27.53 Million36.79%
2003 -โ‚ฌ20.12 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚ฌ13.94 B 2,739.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚ฌ6.56 B 1,237.20%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.46 B 808.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚ฌ0.6 Billion-221.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚ฌ40.46 Million-108.24%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚ฌ0.14 Billion-127.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ1.83 B 273.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚ฌ0.29 B-40.06%๐Ÿ‡บ๐Ÿ‡ธ USA